openPR Logo
Press release

Rising Prevalence Of Hemophilia A To Drive Growth In The Market: A Key Factor Shaping the Future of the Nuwiq (Vihuma) Market in 2025

02-20-2025 12:41 PM CET | Health & Medicine

Press release from: The Business Research Company

Nuwiq (Vihuma) Market Size

Nuwiq (Vihuma) Market Size

What Are the Projections for the Size and Growth Rate of the Nuwiq (Vihuma) Market?
The market size for nuwiq (vihuma) has seen a $XX (CAGR) growth in recent years. The market is projected to increase from $XX million in 2024 to $XX million in 2025, indicating a compound annual growth rate (CAGR) of $XX%. This growth observed in the historical period can be linked to a variety of factors. These include the approval of new recombinant factor VIII therapies, increased awareness about bleeding disorders and the various treatment options available, a rising demand for more effective hemophilia therapies, growth in the number of hemophilia treatment centers globally, and an increase in funding and investment towards research in hemophilia.

In the coming years, a significant increase of $XX (CAGR) is predicted in the nuwiq (vihuma) market, anticipated to escalate to a value of $XX million by 2029, exhibiting a Compound Annual Growth Rate (CAGR) of $XX%. Factors contributing to this promising forecast include the constant surge in global healthcare expenses, broader insurance coverage for hemophilia treatments, increasing public awareness campaigns addressing rare diseases, escalating demand for prophylactic treatments to control bleeding episodes and a global increase in hemophilia cases. The future trends indicating this growth entail innovations in domestic-use hemophilia treatment tools, competition between traditional factor VIII treatments and the introduction of gene therapies, the incorporation of AI technology for customized hemophilia treatment, growing public-private collaborations for funding hemophilia-oriented research, and the use of digital platforms to enhance patient education about hemophilia care.

What Are the Main Catalysts for Growth in the Nuwiq (Vihuma) Market?
The growth of the Nuwiq (Vihuma) market is anticipated to be fueled by the increasing incidence of Hemophilia A. Hemophilia A is a genetic bleeding anomaly triggered by a deficiency or dysfunction of clotting factor VIII, resulting in extended bleeding episodes. The emergence of Hemophilia A is escalating owing to enhanced diagnostic approaches, heightened awareness, and improved patient survival rates. Nuwiq (Vihuma) aids Hemophilia A by offering a recombinant form of factor VIII to substitute the deficient or absent clotting protein, thus facilitating efficient clotting of blood and avoiding or controlling bleeding episodes. For example, in November 2023, data from the National Library of Medicine, a medical library based in the US, revealed that as of July 18, 2022, a total of 10,276 people with hemophilia were registered from 87 treatment centers across 40 countries. Roughly half (49%, n = 5084) of these patients had severe hemophilia, with 99% being males, 85% diagnosed with Hemophilia A, and 67% hailing from low- and middle-income countries. As a result, the escalating worldwide incidence of Hemophilia A is propelling the growth of the Nuwiq (Vihuma) market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20268&type=smp

Which Businesses Are at the Forefront of Nuwiq (Vihuma) Market Development?
Major companies operating in the nuwiq (vihuma) market are Octapharma AG

How Is the Nuwiq (Vihuma) Market Segmented?
The nuwiq (vihuma) market covered in this report is segmented -

1) By Indication: On-Demand Treatment; Prophylaxis; Perioperative Management
2) By Distribution Channel: Direct Sales; Pharmacies; Online Pharmacies
3) By End User: Hospitals; Home Care; Specialized Clinics

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/nuwiq-vihuma-global-market-report

Where Is the Nuwiq (Vihuma) Market Growth Most Prominent?
North America was the largest region in the nuwiq (vihuma) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuwiq (vihuma) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Nuwiq (Vihuma) Global Market Report?

- Market Size Analysis: Analyze the nuwiq (vihuma) Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the nuwiq (vihuma) Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall nuwiq (vihuma) market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the nuwiq (vihuma) market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20268

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rising Prevalence Of Hemophilia A To Drive Growth In The Market: A Key Factor Shaping the Future of the Nuwiq (Vihuma) Market in 2025 here

News-ID: 3878849 • Views:

More Releases from The Business Research Company

Company Registration Service Market Landscape 2025: Forecast Data and Growth Strategy Insights
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Company Registration Service Market Through 2025? The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecasts, and Growth Drivers
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025? In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market in 2025: Advancement In Digital Insurance Platforms Transforms Small And Medium Enterprises Coverage With Integrated, Data-Driven Solutions
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025? The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due To Rising Environmental Monitoring Requirements: Strengthening the Growth Trajectory of the Combustion Emissions Analyzer Market
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025? In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth

All 5 Releases


More Releases for Nuwiq

Rising Cancer Incidence Fuels Growth Of The Market: Key Factor Driving The Growt …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. What Is the Expected Nuwiq (Vihuma) Market Size During the Forecast Period? In recent times, the nuwiq (vihuma) market has shown a XX (HCAGR). The market is estimated to expand from $XX million in 2024 to $XX million in 2025, growing at a compound annual growth rate (CAGR) of XX%. This upward
Comprehensive Nuwiq Vihuma Market Insights: Forecasting Size, Growth, and Compet …
What combination of drivers is leading to accelerated growth in the nuwiq vihuma market? Finally, the Nuwiq (Vihuma) market will grow with the increasing prevalence of hemophilia A, a genetic bleeding disorder caused by a deficiency of clotting factor VIII. The condition is becoming more widely diagnosed, and Nuwiq, a recombinant form of factor VIII, helps manage bleeding episodes in hemophilia A patients. According to the National Library of Medicine, nearly
Blood Clotting Factors Market to Grow with Leading Key Players - Roche AG, Bayer …
Blood Clotting Factors Market is predicted at a CAGR of 6.9% during the forecast period (2024-2031). Blood Clotting Factors Market analysis, according to DataM Intelligence, offers more than just an overview, it investigates the underlying aspects of the sector. The study provides an overview, the research explores the hidden aspects of the sector, breaking down its intricate dynamics, charting regional dominance, spotting demand patterns, and spotting prospective breakthroughs that could influence
Hemophilia A Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies …
Hemophilia A companies are Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd, Bayer, Ultragenix pharmaceutical, ApcinteX Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Expression Therapeutics, LLC, CSL Behring, ASC Therapeutics, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, 2seventy bio, Generation Bio, Apitope Technology, more. (Albany, USA) DelveInsight's 'Hemophilia A Pipeline Insight 2024' report provides comprehensive global coverage of available,
Hemophilia A Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies …
Hemophilia A companies are Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd, Bayer, Ultragenix pharmaceutical, ApcinteX Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Expression Therapeutics, LLC, CSL Behring, ASC Therapeutics, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, and others. (Albany, USA) DelveInsight's 'Hemophilia A Pipeline Insight 2024' report provides comprehensive global coverage of available,
Hemophilia A Clinical Trials Assessment 2023: FDA Approvals, Treatment drugs, Th …
(New York, USA) DelveInsight's 'Hemophilia A Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline Hemophilia A therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Hemophilia A pipeline domain. To know more in detail about Hemophilia A pipeline report, click here: Hemophilia A Pipeline Insight https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr For Hemophilia A emerging drugs, the Hemophilia A